MRNA vaccine takes on glioblastoma in first human trial

NCT ID NCT05938387

Completed Disease control Sponsor: CureVac Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an mRNA vaccine called CVGBM in 37 people with a fast-growing brain cancer called glioblastoma. Participants had already had surgery and radiation. The vaccine aims to train the immune system to attack remaining cancer cells. The main goal was to check safety and find the right dose, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CVGBM mRNA vaccine
What this could lead to: If this vaccine proves safe and effective, it could offer a new way to help the immune system fight glioblastoma and potentially slow tumor regrowth.
What could go wrong: This is a very early Phase 1 trial with only 37 participants, focused on safety, not effectiveness. The vaccine may not work, and side effects are unknown. It also requires a specific genetic type (HLA), so it won't help everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA WITH MOLECULAR SIGNATURE OF UNMETHYLATED GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

CHU de Liège

Liège, Belgium
Erasmusmc Cancer institute

Rotterdam, South Holland, Netherlands
Neurosurgical Clinic at the LMU Munich

München, Germany
Universitair Ziekenhuis Brussel - PPDS

Brussels, Belgium
Universitatsklinikum Leipzig

Leipzig, Saxony, Germany
University Clinic Heidelberg

Heidelberg, Baden-Wurttemberg, Germany
University Clinic Regensburg

Regensburg, Bavaria, Germany
University Hospital Essen

Essen, North Rhine-Westphalia, Germany
Universitätsklinikum Bonn

Bonn, North Rhine-Westphalia, Germany
Universitätsklinikum Frankfurt

Frankfurt am Main, Hesse, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitätsklinikum Tübingen

Tübingen, Baden-Wurttemberg, Germany
Universitätsmedizin Mannheim

Mannheim, Baden-Wurttemberg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.